These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35915668)

  • 1. De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.
    Tasoulis MK; Heil J; Kuerer HM
    Curr Breast Cancer Rep; 2022; 14(4):135-141. PubMed ID: 35915668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Downs-Canner S; Weiss A
    Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response.
    Ryu JM; Lee H; Han W; Lee HB; Ahn SG; Kim HJ; Park HS; Choi JS; Kim H; Cho WK; Lee JE
    J Breast Cancer; 2024 Apr; 27(2):130-140. PubMed ID: 38685868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer.
    Lim DW; Greene BD; Look Hong NJ
    Ann Surg Oncol; 2021 Oct; 28(10):5495-5506. PubMed ID: 34374914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society.
    Ryu JM; Choi HJ; Park EH; Kim JY; Lee YJ; Park S; Lee J; Park HK; Nam SJ; Kim SW; Lee JH; Lee JE;
    J Breast Cancer; 2022 Apr; 25(2):94-105. PubMed ID: 35506578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.
    Hashem M; Rehman S; Salhab M
    Cureus; 2024 Feb; 16(2):e55230. PubMed ID: 38558735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
    Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Importance of Axillary Lymph Node Response to Neoadjuvant Systemic Therapy on Axillary Surgery in Breast Cancer-A Single Center Experience.
    Grašič Kuhar C; Geiger J; Schwab FD; Heinzelmann-Schwartz V; Vetter M; Weber WP; Kurzeder C
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
    Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.
    Sharma P; Connolly RM; Roussos Torres ET; Thompson A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-16. PubMed ID: 32315235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
    Spring LM; Bar Y; Isakoff SJ
    J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy.
    Shi Z; Wang X; Qiu P; Liu Y; Zhao T; Sun X; Chen P; Wang C; Zhang Z; Cong B; Wang Y
    Gland Surg; 2021 Jan; 10(1):166-174. PubMed ID: 33633973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
    Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
    Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice.
    Cavalcante FP; Millen EC; Novita GG; Zerwes FP; Mattar A; Machado RHS; Frasson AL
    Chin Clin Oncol; 2023 Feb; 12(1):6. PubMed ID: 36922355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
    Gharzai LA; Szczygiel LA; Shumway DA; Bandos H; Julian TB; Mamounas EP; White J; De Los Santos JF; Basik M; Ganz PA; Jagsi R
    Breast Cancer Res Treat; 2021 Jun; 187(3):777-784. PubMed ID: 33740205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.